PR Newswire

The newsfeed available here is provided by our content partner PR Newswire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
System-State: Number of processed items 39.362 Notifications successully processed since Inception
PR Newswire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US28176E1082
State: 17.08.2024 | 11PM
Do you already know our new terminal view? Click here.
FIGI: BBG000BRXP69
EW

Edwards Lifesciences Corporation
GICS: - · Sector: Healthcare · Sub-Sector: Medical Devices
NAME
Edwards Lifesciences Corporation
ISIN
US28176E1082
TICKER
EW
MIC
XNYS
REUTERS
EW.N
BLOOMBERG
EW US
Sat, 16.11.2024       Edwards Lifesciences

RADNOR, Pa., Nov. 16, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is December 13, 2024.

Sat, 16.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 15, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024 – July 24, 2024Lead Plaintiff Deadline: December 13, 2024

If you wish to serve as lead plaintiff of the Edwards Lifesciences lawsuit, you can submit your contact information at www.glancylaw.com/cases/edwards-lifesciences-corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

Fri, 15.11.2024       Edwards Lifesciences

NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

Fri, 15.11.2024       Edwards Lifesciences

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Thu, 14.11.2024       Edwards Lifesciences

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards Lifesciences as well as certain of Edwards Lifesciences' executives with violations of the Securities Exchange Act of 1934.

Thu, 14.11.2024       Edwards Lifesciences

NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).

Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Wed, 13.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Wed, 13.11.2024       Edwards Lifesciences

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), of the important December 13, 2024 lead plaintiff deadline.

So what: If you purchased Edwards Lifesciences Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Tue, 12.11.2024       Edwards Lifesciences

BENSALEM, Pa., Nov. 12, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024 – July 24, 2024Lead Plaintiff Deadline: December 13, 2024

Investors suffering losses on their Edwards Lifesciences investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email to howardsmith@howardsmithlaw.com.

Tue, 12.11.2024       Edwards Lifesciences

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

Mon, 11.11.2024       Edwards Lifesciences

NEW YORK, Nov. 11, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).

Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Sun, 10.11.2024       Edwards Lifesciences

RADNOR, Pa., Nov. 10, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.

Sun, 10.11.2024       Edwards Lifesciences

SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit.  Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards Lifesciences as well as certain of Edwards Lifesciences' executives with violations of the Securities Exchange Act of 1934.

Fri, 08.11.2024       Edwards Lifesciences

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 8, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Fri, 08.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Thu, 07.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 7, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024 – July 24, 2024Lead Plaintiff Deadline: December 13, 2024

If you are a shareholder who suffered a loss, click here to participate.

Thu, 07.11.2024       Edwards Lifesciences

NEW YORK, Nov. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).

Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Tue, 05.11.2024       Edwards Lifesciences

SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit.  Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards Lifesciences as well as certain of Edwards Lifesciences' top executives with violations of the Securities Exchange Act of 1934.

Tue, 05.11.2024       Edwards Lifesciences

NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:

Mon, 04.11.2024       Edwards Lifesciences

LOS ANGELES, Nov. 4, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE: EW) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.